Deborah A Lannigan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1619736/publications.pdf

Version: 2024-02-01

24 papers	1,274 citations	567281 15 h-index	713466 21 g-index
24 all docs	24 docs citations	24 times ranked	1485 citing authors

#	Article	IF	Citations
1	pp90^{rsk1} Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167. Molecular and Cellular Biology, 1998, 18, 1978-1984.	2.3	324
2	Estradiol-induced Phosphorylation of Serine 118 in the Estrogen Receptor Is Independent of p42/p44 Mitogen-activated Protein Kinase. Journal of Biological Chemistry, 1998, 273, 13317-13323.	3.4	178
3	Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Research, 2005, 65, 1027-34.	0.9	177
4	RSK1 drives p27^{Kip1}phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9268-9273.	7.1	142
5	Sustained activation of the HER1â€“ERK1/2â€“RSK signaling pathway controls myoepithelial cell fate in human mammary tissue. Genes and Development, 2011, 25, 1641-1653.	5.9	66
6	Structural basis for the activity of the RSK-specific inhibitor, SL0101. Bioorganic and Medicinal Chemistry, 2007, 15, 5018-5034.	3.0	62
7	Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 2598-2608.	4.1	52
8	RSK in tumorigenesis: Connections to steroid signaling. Steroids, 2010, 75, 191-202.	1.8	46
9	Insights into the Inhibition of the p90 Ribosomal S6 Kinase (RSK) by the Flavonol Glycoside SL0101 from the 1.5 Ã... Crystal Structure of the N-Terminal Domain of RSK2 with Bound Inhibitor. Biochemistry, 2012, 51, 6499-6510.	2.5	39
10	Synthesis and Structureâ€“Activity Relationship Study of 5a-Carbasugar Analogues of SL0101. ACS Medicinal Chemistry Letters, 2015, 6, 95-99.	2.8	30
11	Stereoselective Synthesis and Evaluation of C6â€³-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2. Organic Letters, 2017, 19, 2410-2413.	4.6	26
12	Improving the Affinity of SL0101 for RSK Using Structure-Based Design. ACS Medicinal Chemistry Letters, 2013, 4, 175-179.	2.8	25
13	Ribosomal S6 kinase (RSK) modulators: a patent review. Expert Opinion on Therapeutic Patents, 2016, 26, 1061-1078.	5.0	21
14	De Novo Synthesis and Biological Evaluation of C6â€³-Substituted C4â€³-Amide Analogues of SL0101. Organic Letters, 2014, 16, 5996-5999.	4.6	20
15	ERÎ±-Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis. Cancer Research, 2018, 78, 2014-2025.	0.9	17
16	RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha. Cell Reports, 2020, 32, 107931.	6.4	13
17	Regioselective Synthesis of a C-4â€²â€² Carbamate,C-6â€²â€² n-Pr Substituted Cyclitol Analogue of SL0101. Organic Letters, 2020, 22, 1448-1452.	4.6	12
18	Synthesis and Biological Evaluation of 4â€²-Substituted Kaempfer-3-ols. Journal of Organic Chemistry, 2020, 85, 4279-4288.	3.2	10

#	Article	IF	Citations
19	The affinity of RSK for cylitol analogues of SL0101 is critically dependent on the B-ring C-4â€²-hydroxy. Chemical Communications, 2020, 56, 3058-3060.	4.1	7
20	Identifying requirements for RSK2 specific inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1798-1809.	5.2	4
21	ERK1/2â€RSK regulation of oestrogen homeostasis. FEBS Journal, 2022, , .	4.7	2
22	FACS protocol for direct comparison of cell populations isolated from mice. STAR Protocols, 2021, 2, 100270.	1.2	1
23	RSK2 and ERÎ± comrades-in-arms in homeostasis and transformation. Molecular and Cellular Oncology, 2020, 7, 1825916.	0.7	0
24	ERK1/2â€RSK Regulation of Cell Fate in Human Mammary Ductal Development. FASEB Journal, 2013, 27, 455.2.	0.5	0